Novonesis Overview

  • Year Founded
  • 1873

Year Founded

  • Status
  • Public

  • Employees
  • 11,641

Employees

  • Stock Symbol
  • NSIS B

Stock Symbol

  • Investments
  • 43

  • Share Price
  • $64.58
  • (As of Thursday Closing)

Novonesis General Information

Description

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Contact Information

Formerly Known As
Chr. Hansen, Novozymes
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Biologiens Vej 2
  • 2800 Lyngby
  • Denmark
+45 44
Primary Industry
Biotechnology
Stock Exchange
CSE
Corporate Office
  • Biologiens Vej 2
  • 2800 Lyngby
  • Denmark
+45 44

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novonesis Stock Performance

As of 19-Nov-2026, Novonesis’s stock price is $64.58. Its current market cap is $30.1B with 466M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$64.58 $66.33 $51.66 - $72.33 $30.1B 466M 648K $1.70

Novonesis Financials Summary

As of 30-Sep-2026, Novonesis has a trailing 12-month revenue of $5.08B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 32,808,998 33,213,606 28,273,108 15,204,282
Revenue 5,079,878 4,689,798 4,148,226 2,599,362
EBITDA 1,094,587 1,540,292 1,093,677 781,475
Net Income 791,807 658,304 330,906 439,214
Total Assets 19,081,332 19,203,961 15,812,114 4,210,910
Total Debt 3,549,931 3,530,199 1,869,700 1,154,037
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Novonesis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novonesis‘s full profile, request access.

Request a free trial

Novonesis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became t
Biotechnology
Lyngby, Denmark
11,641 As of 2025

Seattle, WA
 

Hoersholm, Denmark
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novonesis Competitors (18)

One of Novonesis’s 18 competitors is Arzeda, a Venture Capital-Backed company based in Seattle, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arzeda Venture Capital-Backed Seattle, WA
Chr. Hansen Formerly PE-Backed Hoersholm, Denmark
Advanced Enzyme Technologies Formerly PE-Backed Thane, India
GSK Corporation London, United Kingdom
Evogene Formerly VC-backed Rehovot, Israel
You’re viewing 5 of 18 competitors. Get the full list »

Novonesis Patents

Novonesis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026077488-A2 Use of protease to degrade animal hairballs Pending 27-Jun-2025
WO-2026077488-A3 Use of protease to degrade animal hairballs Pending 27-Jun-2025
WO-2026234237-A1 Fermentation method Pending 09-May-2025
WO-2026233909-A1 Method for packaging a meat product Pending 05-May-2025
WO-2026219898-A2 Citrate-deficient lacticaseibacillus rhamnosus strains and uses thereof Pending 16-Apr-2025 A23C9/1234
To view Novonesis’s complete patent history, request access »

Novonesis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novonesis Investments & Acquisitions (43)

Novonesis’s most recent deal was a Merger/Acquisition with Microbiogen. The deal was made on 01-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Microbiogen 01-Oct-2026 Merger/Acquisition Coal and Consumable Fuels Equipment
TurtleTree 08-Jul-2026 Later Stage VC Food Products
Meihua Group (Production Facility in Rayong, Thailand) 08-Apr-2026 Corporate Asset Purchase Buildings and Property
Feed Enzyme Alliance 02-Jun-2025 Merger/Acquisition Food Products
Chr. Hansen 29-Jan-2024 Merger/Acquisition Biotechnology
You’re viewing 5 of 43 investments and acquisitions. Get the full list »

Novonesis ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

16.31 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Chemicals

Industry

of 503

Rank

Percentile

Specialty Chemicals

Subindustry

of 165

Rank

Percentile

To view Novonesis’s complete esg history, request access »

Novonesis Exits (10)

Novonesis’s most recent exit was on 13-Dec-2018 from Plant Response. The exit was categorized as with 7 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Plant Response 13-Dec-2018 Completed
  • 7 buyers
Maabjerg Energy Center BioGas 04-Apr-2017 Completed
  • 4 buyers
AgBiome 20-Aug-2015 Completed
  • 10 buyers
Plant Response 07-Aug-2015 Completed
  • 5 buyers
AgBiome 14-Nov-2014 Early Stage VC Completed
  • 6 buyers
You’re viewing 5 of 10 exits. Get the full list »

Novonesis Affiliates

Subsidiaries (11)

Name Industry Location Year Founded
Jupiter Beteiligungsgesellschaft mbH Nienburg/Weser, Germany 2020
Microbiome Labs Franklinton, NC 2012
Novonesis Plant Biosolutions Kongens Lyngby, Denmark 2007
Synergia Life Sciences Mumbai, India 2004
Novozymes France Le Pecq, France 2001
You’re viewing 5 of 11 affiliates. Get the full list.  »

Novonesis FAQs

  • When was Novonesis founded?

    Novonesis was founded in 1873.

  • Where is Novonesis headquartered?

    Novonesis is headquartered in Lyngby, Denmark.

  • What is the size of Novonesis?

    Novonesis has 11,641 total employees.

  • What industry is Novonesis in?

    Novonesis’s primary industry is Biotechnology.

  • Is Novonesis a private or public company?

    Novonesis is a Public company.

  • What is Novonesis’s stock symbol?

    The ticker symbol for Novonesis is NSIS B.

  • What is the current stock price of Novonesis?

    As of 19-Nov-2026 the stock price of Novonesis is $64.58.

  • What is the current market cap of Novonesis?

    The current market capitalization of Novonesis is $30.1B.

  • What is Novonesis’s current revenue?

    The trailing twelve month revenue for Novonesis is $5.08B.

  • Who are Novonesis’s competitors?

    Arzeda, Chr. Hansen, Advanced Enzyme Technologies, GSK, and Evogene are some of the 18 competitors of Novonesis.

  • What is Novonesis’s annual earnings per share (EPS)?

    Novonesis’s EPS for 12 months was $1.70.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process